FDA-approved Anticancer Drug Library

Cat.No.L8000

A unique collection of 1728 approved drugs with potential anticancer activity used for high throughput screening (HTS) and high content screening (HCS).

Customise Your Library:

Specific Compounds
Quantities
96 or 384 well Plate Map
Dry/solid or DMSO solution

Cited by 327 Publications

FDA-approved Anticancer Drug Library Contents

Description & Advantages

•A unique collection of 1728 approved drugs with potential anticancer activity used for high throughput screening(HTS) and high content screening(HCS);

•All drugs were from approved institutions such as FDA,EMA,HMA,CFDA,PMDA,or pharmacopoeia such as USP,BP,EP,JP,Ph.Int,etc;

•Bioactivity and safety confirmed by clinical trials;

• Structurally diverse, medicinally active, and cell permeable;

• Rich documentation with structure and customer reviews;

• NMR and HPLC validated to ensure high purity.

Product Details

Formulation	1554 compounds pre-dissolved in 10mM DMSO, 111 compounds pre-dissolved in 10mM water, 54 compounds pre-dissolved in 2mM DMSO and 9 compounds pre-dissolved in 2mM water
Container	96 Deep Well Plate Sealed With Aluminium Foil
Stability	12 months	-20°C	in DMSO
Stability	24 months	-80°C	in DMSO
Shipping	Blue ice or dry ice

Case Studies using Selleck Compound Libraries

Application of GPCR Compound Library in liver cancer (This article was published in Nature (IF

Nature.2019;574(7777):268-272
Application of Kinase Inhibitor Library in colorectal cancer (This article was published in Nature Communications (IF

Nat Commun. 2019 16;10(1):2197
Application of FDA-approved Drug Library in antivirus (This article was published in Cell Research (IF

Cell Res. 2019;29(9):739-753
Application of FDA-approved Drug Library in metabolism (This article was published in Movement Disorders (IF

Mov Disord. 2019;34(3):323-334
Application of Epigenetics Compound Library in acute lymphoblastic leukaemia (This article was published in Blood (IF

Blood. 2019 17;134(16):1323-1336
Application of Inhibitor Library in tumour immunology (This article was published in Cancer Immunol Res (IF

Cancer Immunol Res.2017;5(9):790-803